Brighter tomorrow

The dedicated team at Volition have a shared goal – to save lives by revolutionizing the way disease, and especially cancer, is diagnosed throughout the world.

An interview with Cameron Reynolds

Early diagnosis is key

Cancer is the second leading cause of death and is responsible for 1-in-6 deaths worldwide each year. It is widely accepted that the best way of tackling cancer is for patients to receive an early diagnosis, as this improves their chances of surviving cancer. Volition is developing simple, easy to use blood-based tests to diagnose a range of cancers and other diseases.

We believe that Nu.Q™ will provide a low-cost routine blood test allowing doctors to check off an extra box along with other routine blood tests, such as cholesterol and PSA, during a single visit, and that this is currently the only credible way of taking compliance with screening above 80%.

X Early Diagnosis
Find out

“Screening increases the chances of detecting certain cancers early when they are most likely to be curable.”

American Cancer Society

In the U.S. alone, one person dies of a cancer-related death every minute.

The ongoing problem

Cancer is the second leading cause of death worldwide with over 18.1 million new cases diagnosed each year. This causes over 9.6 million deaths worldwide and is expected to increase to over 16 million deaths by 2040.

X Large Quote

Current cancer diagnosis involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing.

Dr. Jake Micallef, PhD, MBACSO

A simple test, with a small amount of blood.

For more information on Nu.Q, click here

Nu.Q runs on simple low-cost ELISA technology, which can utilize other tests for even higher accuracy.

Rethinking the approach to cancer

Nu.Q represents a powerful step change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis.

Intellectual Property

Believed to be the only company working on ELISA measurement for epigenetically modified circulating nucleosomes.

As of March 2019:

  • 20
    Patent families
  • 7
    Patents granted in the U.S.
  • 7
    Patents granted in the E.U.
  • 25
    Additional patents granted worldwide
  • 106
    Patents pending
Recent Videos
  • Proactive Investors interview Cameron Reynolds, CEO
    Proactive Investors interview Cameron Reynolds, CEO
    Play video
  • 2019 Full Year Results - an interview with Cameron Reynolds
    2019 Full Year Results - an interview with Cameron Reynolds
    Play video
Recent Press Releases
  • VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
  • VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update